Filing Details
- Accession Number:
- 0001179022-18-000048
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-06-12 16:48:49
- Reporting Period:
- 2018-06-08
- Accepted Time:
- 2018-06-12 16:48:49
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1133416 | Galectin Therapeutics Inc | GALT | Pharmaceutical Preparations (2834) | 043562325 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1266773 | W Jack Callicutt | C/O Galectin Therapeutics, Inc. 4960 Peachtree Industrial Blvd., Ste 240 Norcross GA 30071 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2018-06-08 | 100,000 | $0.87 | 101,260 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2018-06-08 | 100,000 | $5.75 | 1,260 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2018-06-11 | 20,000 | $1.37 | 21,260 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2018-06-11 | 20,000 | $6.38 | 1,260 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock option (right to buy) | Disposition | 2018-06-08 | 100,000 | $0.00 | 100,000 | $0.87 |
| Common Stock | Stock option (right to buy) | Disposition | 2018-06-11 | 20,000 | $0.00 | 20,000 | $1.37 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2026-12-03 | No | 4 | M | Direct | |
| 18,000 | 2026-01-20 | No | 4 | M | Direct |
Footnotes
- The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2018.
- The options vested as follows: 25% on December 3, 2016, the grant date; 25% on July 1, 2017; and 50% on December 31, 2017.
- The options vested as follows: 25% on January 20, 2016, the grant date, with the remainder vesting ratably on a monthly basis over a three year period.
- The shares were sold in multiple transactions at prices ranging from $5.50 to $6.00. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- The shares were sold in multiple transactions at prices ranging from $6.25 to $6.50. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
Billionaire Hedge Funds
